Glatopa

Indicated For

relapsing forms of multiple sclerosis (MS)

About This Medication

# Glatopa Co-Pay Assistance Program Patient Guide: How to Get Glatopa at Low or No Cost ## About This Program The **Glatopa Co-Pay Assistance Program**, offered by Sandoz (the manufacturer of Glatopa), helps eligible patients reduce their out-of-pocket costs for this FDA-approved multiple sclerosis medication. Many patients qualify for **$0 monthly co-pays** on their Glatopa prescriptions through this program. ## About Glatopa (Glatiramer Acetate) Glatopa is an FDA-approved generic version of Copaxone, a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). It is therapeutically equivalent to brand-name Copaxone, meaning it works the same way in the body with identical safety and effectiveness. Glatopa is available in two formulations: - **20 mg/mL**: Administered once daily via subcutaneous injection - **40 mg/mL**: Administered three times per week (at least 48 hours apart) via subcutaneous injection Your neurologist will determine which strength is appropriate for your MS treatment plan. ## Who Qualifies for This Program The Glatopa Co-Pay Assistance Program is designed for **commercially insured patients** in the United States. To be eligible, you typically need: - Active commercial insurance coverage for Glatopa - A valid prescription from your healthcare provider - U.S. residency - Not enrolled in government insurance programs (Medicare or Medicaid) **Important Note**: Medicare beneficiaries cannot use manufacturer co-pay cards. However, Glatopa's lower baseline cost compared to brand-name Copaxone typically results in significantly lower Medicare Part D co-pays. ## Income Eligibility The search results do not specify income thresholds for the Glatopa Co-Pay Assistance Program. Income requirements may vary or may not apply to this particular co-pay card program. Contact Sandoz directly at **(855) 452-8672** to confirm your eligibility based on your specific financial situation. ## Insurance Requirements This program is exclusively for **commercially insured patients**. Your commercial insurance must cover Glatopa for you to qualify. If you have Medicare, Medicaid, or other government insurance, you are not eligible for this co-pay card program, though you may still benefit from Glatopa's lower cost compared to brand-name Copaxone. ## How to Apply: Step-by-Step ### Step 1: Gather Your Information Before applying, have the following ready: - Your prescription from your neurologist - Your commercial insurance information - Your contact information (phone number and mailing address) ### Step 2: Choose Your Application Method You can enroll in the Glatopa Co-Pay Assistance Program in three ways: 1. **Online**: Visit the Glatopa website and complete the enrollment form 2. **Phone**: Call **1-855-GLATOPA (1-855-452-8672)** to speak with a representative. Financial assistance specialists are available **8:00 AM to 8:00 PM ET** 3. **Text**: Text **"START"** to **23519** to begin the enrollment process (message and data rates may apply) ### Step 3: Complete Your Application Provide the requested information about your prescription, insurance coverage, and contact details. A Sandoz representative will review your eligibility. ### Step 4: Receive Your Co-Pay Card Once approved, you will receive your Glatopa co-pay card, which you can use at participating pharmacies to reduce your out-of-pocket costs. ## Application Timeline and Delivery The search results do not specify the exact processing time for applications or the delivery method for co-pay cards. Contact Sandoz at **(855) 452-8672** to ask about: - How long approval typically takes - When you can expect to receive your co-pay card - Whether the card can be sent electronically or by mail ## What Happens If Your Application Is Denied If you are denied enrollment in the Glatopa Co-Pay Assistance Program, consider these alternatives: - **Verify your eligibility**: Confirm that you have commercial insurance and meet all program requirements. Call **(855) 452-8672** to discuss why your application was denied. - **Switch from brand-name Copaxone**: If you were previously using brand-name Copaxone and your co-pay card ran out, switching to Glatopa with a fresh co-pay assistance benefit can help maintain affordable treatment. - **Explore other assistance**: Contact your insurance company to ask about other cost-reduction programs or prior authorization options. - **Speak with your healthcare provider**: Your neurologist may have information about other patient assistance programs or treatment options. ## Refills and Ongoing Support Once enrolled in the Glatopa Co-Pay Assistance Program, Sandoz provides comprehensive ongoing support through **GlatopaCare**, a free patient support program that includes: - Co-pay card management and monitoring throughout the year - Injection technique training (in-home or by phone) - Auto-injector device provision and instruction - 24/7 pharmacist access for questions about Glatopa - Insurance navigation and prior authorization handling - Coordination with your healthcare provider for prescription management You can reach the GlatopaCare team at **(855) 452-8672** anytime, day or night. ## Reauthorization The search results do not specify whether annual reauthorization is required for the Glatopa Co-Pay Assistance Program. Contact Sandoz at **(855) 452-8672** to ask about: - Whether your co-pay card needs to be renewed annually - When renewal should occur - How to renew your benefits ## Important Disclaimer This guide provides general information about the Glatopa Co-Pay Assistance Program based on publicly available information. Program details, eligibility requirements, and benefits may change. For the most current and accurate information, contact Sandoz directly: - **Phone**: 1-855-GLATOPA (1-855-452-8672) - **Website**: glatopa.com - **Hours for Financial Assistance**: 8:00 AM to 8:00 PM ET - **Hours for General Inquiries**: 24 hours, 7 days a week Always consult with your healthcare provider and insurance company to understand your specific coverage and eligibility.

Program information last verified: March 25, 2026